Glaucoma Cell Biology Group, The Westmead Institute for Medical Research, NSW, Australia; Discipline of Ophthalmology, Sydney Medical School, University of Sydney, NSW, Australia.
Glaucoma Cell Biology Group, The Westmead Institute for Medical Research, NSW, Australia; Discipline of Ophthalmology, Sydney Medical School, University of Sydney, NSW, Australia.
Ophthalmology. 2018 Feb;125(2):179-192. doi: 10.1016/j.ophtha.2017.08.028. Epub 2017 Nov 1.
Modulating conjunctival wound healing has the potential to improve outcomes after glaucoma filtration surgery and for several ocular disorders, including ocular cicatrial pemphigoid, vernal keratoconjunctivitis, and pterygium. Although anti-inflammatories and antimetabolites have been used with success, these nonspecific agents are not without their complications. The search for novel and more targeted means to control conjunctival fibrosis without such limitations has brought much attention to the regulation of fibroblast proliferation, differentiation, extracellular matrix production, and apoptosis. This review provides an update on where we stand with current antifibrotic agents and outlines the strategies that novel agents use, as they evolve from the bench to the bedside.
调节结膜创伤愈合有可能改善青光眼滤过性手术的结果，也可能改善几种眼部疾病的结果，包括眼瘢痕性类天疱疮、春季性角结膜炎和翼状胬肉。尽管成功地使用了抗炎药和抗代谢药，但这些非特异性药物并非没有并发症。寻找新的、更有针对性的方法来控制结膜纤维化，而没有这些限制，因此人们非常关注对成纤维细胞增殖、分化、细胞外基质产生和细胞凋亡的调节。本文综述了当前抗纤维化药物的现状，并概述了新型药物从实验室到临床应用所采用的策略。
